Evaluation of Radiofrequency Catheter Ablation Settings for Variable Atrial Tissue Depth and Flow Conditions

Desmond Dillon-Murphy, David Nordsletten, Navjeevan Soor, Henry Chubb, Mark O’Neill, Adelaide de Vecchi, Oleg Aslanidi

1 Department of Biomedical Engineering, King’s College London, London, United Kingdom
2 Department of Bioengineering, Imperial College London, London, United Kingdom

Abstract

Catheter ablation (CA) is a potentially curative therapy for paroxysmal atrial fibrillation, however up to 50% of patients may require a repeat procedure to achieve the best results. While this may be due to insufficient radiofrequency (RF) energy delivery to achieve transmural, contiguous ablation lesions (TAL), excessive RF application may result in extracardiac injury and complications. We aim to evaluate optimal RFCA temperature settings for variable atrial tissue depth and blood flow conditions.

Heat spread in atrial tissue and blood was simulated using the Pennes bioheat equation with an additional convective term in the blood. The minimum catheter contact time required for TAL formation increased with increasing either atrial wall thickness (AWT) or laminar flow velocity (LFV). Thus, during ablation of atrial tissue regions with AWT of 1 and 5.5 mm and LFV of 0.1 m/s, TALs were formed in 12 and 153 s, respectively. When LFV was increased to 1.2 m/s, the TAL formation time increased to 21 and 174 s. The maximum temperature in the blood volume stayed below the coagulation risk threshold of 70°C for all AWT values with LFVs over 0.6 m/s, but raised above the threshold for LFV ≤ 0.6 m/s and AWT > 1.5 mm.

This study demonstrates the potential for optimizing RFCA settings according to atrial tissue depth and blood flow conditions.

1. Introduction

Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting over 30 million people worldwide [1]. It is characterised by irregular, rapid electrical activations of the atria and carries a high risk of heart failure and stroke. Radiofrequency catheter ablation (RFCA) is gradually supplanting antiarrhythmic drug therapy as a front-line treatment for AF termination. This procedure delivers RF energy via a catheter to produce produce electrically inert, transmural lesions in the myocardium to isolate or remove areas contributing to the generation or maintenance of the activity sustaining AF (e.g., drivers near the pulmonary veins, PVs) [2]. In the absence of new electrical drivers, reoccurrence of AF may be due to gaps between lesions or a lack of transmurality, which both prevent the complete isolation of the drivers [3].

However, RFCA procedures are not always effective. The success rates for single-procedure PV isolations in paroxysmal AF patients are only 38-70% [1]. In persistent AF, PV isolation alone is not sufficient and further areas of the atrial wall are targeted. Moreover, in 4.5% of patients RFCA procedures can result in major complications [4]. In-vitro studies also suggest that in regions with high blood flow rate and convective cooling, e.g., above the mitral valve, more power must be supplied to achieve transmural lesions, resulting in higher localised temperature, overheating atrial tissue and producing larger lesions [5, 6]. This excessive ablation can cause permanent loss of contractility outside of target areas and heart failure [7].

As blood flow rates vary considerably inside the atria, the lesion size is hard to predict. Additionally, high inter- and intra-patient variations in atrial wall thickness (AWT) [8] presents a major issue when creating the transmural lesions required for effective RFCA treatments. Knowledge of both AWT and blood flow rates could provide clinicians with useful information to optimise the ablation procedure – by using the minimal amount of RF energy and catheter contact time to achieve lesion transmurality. Furthermore, such knowledge could also reduce the risk of complications. For example, PV stenosis can be avoided by minimising catheter contact time at target areas to ensure temperatures stay below risk levels [9].

This study aims to apply computational modelling [10, 11] to simulate RFCA in realistic atrial blood flow and wall thickness settings. This will provide novel information on the minimal catheter contact time required to fully form transmural ablation lesions (TAL) – while also assessing the risks of complications – for specific flow and AWT. The model predictions could potentially be used to improve the efficacy and safety of RFCA procedures in the clinic.
2. Methods

2.1. Thermal model with convection

To simulate the temperature distributions in atrial tissue and blood the Pennes bioheat equation with an additional convective term in the blood was used [11]:

$$\frac{\partial T}{\partial t} = D \nabla^2 T + Q_{cath} - \vec{v} \cdot \nabla T$$  \hspace{1cm} (1)

where

$$D = k / \rho c$$

$$Q_{cath} = \vec{E} \cdot \vec{J} = \sigma (\nabla V)^2$$

$$\vec{E} = \nabla V$$

$$\vec{J} = \sigma \nabla V$$

and the voltage is determined from the Laplace’s equation:

$$\nabla^2 V = 0$$

The variables in the equations above are as follows:

- $c$: heat capacity of the myocardium (J/(kg·K))
- $T$: temperature of the blood or myocardium (K)
- $D$: thermal diffusivity (m$^2$/s)
- $Q_{cath}$: heat applied by the catheter (W/m$^3$)
- $\vec{v}$: blood velocity (m/s)
- $k$: thermal conductivity (W/(m·K))
- $\rho$: density (kg/m$^3$)
- $\sigma$: electric conductivity (S/m)
- $\vec{E}$: electrical field intensity (V/m)
- $\vec{J}$: current density (A/m$^2$)

Heat loss due to perfusion in the myocardium was neglected as nominal relative to the heat applied during ablation. The Arrhenius method was used to evaluate tissue thermal injury leading to the TAL formation:

$$\Omega(t) = \int_0^t A \cdot e^{-\frac{\Delta E}{RT}} dt = \ln \left[ \frac{c(0)}{c(t)} \right]$$  \hspace{1cm} (2)

where $\Omega(t)$ is interpreted as the logarithmic ratio of undamaged tissue at time 0 and ratio of damaged tissue at time $t$; $A$ is the rate factor measuring collision (s$^{-1}$); $\Delta E$ is the energy barrier the tissue must exceed to be denatured (J/mol) and $R$ is universal gas constant (8.314 J/mol·K). If $\Omega(t) = 1$ this indicates 63% probability of irreversible tissue damage and $\Omega(t) > 4.3$ indicates 99% probability.

Equations were solved using the finite difference method on a uniform 3D rectangular domain measuring 50×100×50 voxels with a spatial step of 0.25 mm. The tissue slab measured 50×100×$n$/0.25, where $n$ represented slab thickness in mm, and the remainder of the domain represented blood. The temporal step was set at 5 ms. Throughout the domain an initial temperature was set at 37 °C (310.15 K) and a uniform potential set at 0 V.

Values for the constants were determined from literature used for both blood [12] and myocardium (see Table 1). Blood was assumed to have a haematocrit of 40%.

Table 1. Constants used in the model

<table>
<thead>
<tr>
<th></th>
<th>$\rho$</th>
<th>$c$</th>
<th>$k$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tissue</td>
<td>1,200</td>
<td>3,200</td>
<td>0.55</td>
</tr>
<tr>
<td>Blood</td>
<td>1,060</td>
<td>3,947</td>
<td>0.57</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>$\sigma$</th>
<th>$A$</th>
<th>$\Delta E$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tissue</td>
<td>0.222</td>
<td>1.28×10$^{22}$</td>
<td>145,000</td>
</tr>
<tr>
<td>Blood</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2.2. Ablation simulation settings

To explore the relationship between atrial wall depth, blood flow velocity and TAL formation, a series of atrial tissue slabs with blood volume (see Figure 1) were created with AWT defined between 1.0-5.5 mm [8] in steps of 0.5 mm. For each slab, a series of simulations was performed with a uniform laminar flow velocity (LFV) specified in the blood and varied between 0.0-1.2 m/s [13] in steps of 0.2 m/s. In each simulation, an initial voltage of 10 V was applied to the catheter positioned in the bloodstream on the endocardial surface of the tissue. The simulation continued until some point of the myocardium on the opposite, epicardial surface reached a value of $\Omega \geq 1$, indicating the creation of a transmural lesion through the atrial wall.

3. Results

Figure 1 illustrates ablation simulations in 3D atrial slabs with varying AWT under the blood with varying LFV, with the catheter tip positioned at the tissue-blood interface. Both temperature (left panels) and the $\Omega$-value (right panels) representing tissue damage are mapped, and regions where $\Omega \geq 1$ (corresponding to scar tissue forming the lesion) are highlighted. The extremes of the varying LFV are illustrated – a stagnant 0.0 m/s flow to the highest simulated velocity of 1.2 m/s in steps of 0.2 m/s – for three representative AWT values, 1.0 mm, 3.5 mm and 5.0 mm.

Figure 1 shows that blood flow had a significant impact on the shape of ablation lesions. At zero velocity, the lesion formed in a hemisphere like shape evenly around the region in contact with the catheter tip. This was due to the even spreading of heat around the ablation contact area. When exposed to the flow, the temperature distribution changed, with the higher temperatures being downstream of the catheter tip. This change in the temperature distribution causes the lesion to form as a semi-ellipsoid with
Figure 1. **Temperature distribution in atrial tissue and blood**: The figure shows temperature distributions in transmural cross sections through 3D atrial slabs under the blood volume (left panels), and the respective cross sections and top down projections of the $\Omega$-value (right panels) in the tissue for AWT of 1.0 mm (top), 3.5 mm (middle) and 5.0 mm (bottom) and LBF of 0.0 m/s (left) and 1.2 m/s (right). The position of the catheter tip (red) for each simulation is shown. The regions where $\Omega \geq 1$ indicating a 63 % chance of irreversible tissue damage are highlighted (black). The regions where temperature was recorded being $\geq 70$ °C also are highlighted (white) due to the additional risk of blood clot formation.

the long axis in the direction of flow. The point which first reaches $\Omega \geq 1$ on the opposing side of the atrial wall also changes, shifting from being directly opposite the mid-point of the catheter tip to being at a point downstream.

Figure 1 also shows that higher LFV tended to be associated with lower blood temperatures, and blood was observed to heat to higher temperatures when LFV was low. The figure highlights regions above 70 °C, which have been associated with a higher likelihood of blood clot formation during the ablation process [14].

Figure 2. **Effect of AWT and LFV on the time to full TAL formation**: This was measured as the time when $\Omega$ reached a value $\geq 1$ on the epicardial side of the atrial wall – oppose the catheter tip applied on the endocardium. Here and below, each line represents a different blood velocity.

Figure 2 shows the time to TAL formation (full lesion extending from endocardium to epicardium) against AWT for each value of velocity from 0.0 m/s to 1.2 m/s. The figure suggests that higher flow velocities and thicker atrial wall corresponded to longer times to TAL formation, with the the formation time showing a stronger dependence on the AWT. Note that percentage change in the TAL formation time was similar for AWT values of 1 and 5 mm: in both cases, the lesion took 23% longer to form when LFV was 1.2 m/s rather than zero. The greatest change was seen for AWT of 2.5 mm, where the difference in TAL formation time was 50.38% between LFV of 0.0 and 1.2 m/s. This result suggests that at such intermediate AWT values blood flow has a greater influence on lesion formation.

Figure 3. **Effect of AWT and LFV on the lesion length**: The figure shows length of the long axis of the lesion. Voxels along this axis with $\Omega \geq 1$ were those sampled.

Figure 3 shows the effect varying AWT and blood velocity had on the length of the resulting lesion, with higher velocities associated with longer lesions.

Figure 4 shows the effect varying AWT and LFV had on the blood maximum temperature. The figure suggests that the peak temperatures are observed in low blood velocities.
Figure 4. Effect of AWT and LFV on the maximum blood temperature: The figure shows the maximum temperature recorded in the blood for each simulation.

and higher AWT cases. Interestingly, at 1 mm AWT the highest blood temperatures are recorded at an intermediate LFV of 0.6 m/s. The reason for the peak temperature not being observed at 0.0 m/s, as seen for greater AWT, is due to the faster speed of the TAL formation for lower AWT and LFV which does not allow the blood time to heat up.

4. Discussion

We developed a novel computational approach to evaluate RFCA settings for realistic atrial tissue depth and flow conditions. For the catheter voltage of 10 V (corresponding to RF power of 70 W), the TAL formation time required for achieving effective TALs increased quasi-linearly with both increasing AWT and LFV, with a faster rate of increase for AWT. Both the TAL formation time (Figure 2) and length (Figure 3) can change 10-fold between the condition of low and high AWT and LFV. However, these minimal TAL formation times were generally shorter than catheter contact times in common use. Interestingly, the blood flow had a greater influence on the TAL formation at intermediate AWT values of 2.5 mm, which are average values seen the atrial walls [8]. Risks of the heat-induced blood coagulation due to temperature ≥ 70 °C [14] also varied with AWT and LFV (Figure 4).

Limitations of the study include the consideration of only simple 3D slab geometries and laminar flow conditions. Future studies will focus on combining the current approach with anatomically detailed 3D atrial models [10] and accurate 3D blood flow simulations [15].

In summary, this study demonstrates the potential for optimizing RFCA settings according to variable atrial tissue depth and flow conditions, which can help improve the safety and efficacy of RFCA therapy in the future.

References


Acknowledgements

This research is funded by grants from the British Heart Foundation (PG/10/69/28524) and EPSRC (EP/P013228/1).

Address for correspondence:
Oleg Aslanidi
Department of Biomedical Engineering, King’s College London, St Thomas’ Hospital, London SE1 7EH, United Kingdom
E-mail: oleg.aslanidi@kcl.ac.uk